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ABSTRACT

A method and kit for detection of Mycobacterium Avium
Subspecies Paratuberculosis (MAP) in blood and blood
derivative samples from humans by culture and PCR. Technology can screen for MAP in blood samples from millions of
patients having inflammatory and non-inflammatory bowel
diseases, and the results are used to identify those patients
with MAP for treatment by antibiotics. The method and kit
can monitor and evaluate the outcome of therapy.
18 Claims, 7 Drawing Sheets

U.S. Patent

Feb.10,2009

Sheet 1of7

US 7,488,580 Bl

Sequence ID 1 P90 5-GITCGGGGCCGTCGCTIAGG-3

Figure 1
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Sequence ID 2 P91 5-GAGGTCGATCGCCCACGTGA-3

Figure 2
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Sequence ID 3 AVI 5-ATGTGGTIGCTGTGTTGGATGG-3

Figure 3
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Sequence ID 4 AV2 5-CCGCCGCAATCAACTCCAG-3

Figure 4
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Figure 6A
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PROTOCOL FOR DETECTION OF
MYCOBACTERIUM AV/UM SUBSPECIES
PARATUBERCULOS/S IN BLOOD

may be other etiologies for Crohns or irritable bowel syndrome other than MAP) using a simple blood test. This blood
test can also be used to identify Crohn' s disease patient population with MAP infection. Additonally, this novel blood test
can be used to differentiate IBD patients with MAP infection
from those without MAP infection. Moreover, such tests can
be used to monitor and evaluate treatment after obtaining a
first positive result. Repeat blood tests can determine if the
bacterium is being reduced or eliminated from the system, or
not.

This invention claims the benefit of priority from U.S.
Provisional Patent Application Ser. No. 60/660,417 filed Mar.
10, 2005.
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FIELD OF THE INVENTION
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This invention relates to the detection of the bacterium
Mycobacterium Avium Subspecies Paratuberculosis (MAP),
and in particular to a method and kit for using blood via PCR
and culture to detect patients having the bacterium and ultimately to select those patients having the bacterium for treatments.

SUMMARY OF THE INVENTION

15

BACKGROUND AND PRIOR ART
Inflammatory bowel diseases, such as Crohn's disease or
ulcerative colitis cause inflammation of the gastrointestinal
tract, most commonly the small intestine, with resulting
abdominal pain, difficulty in digesting food, and other symptoms. Clinically diagnosing Crohn's or ulcerative colitis is an
expensive, time consuming process which often requires
some form of anesthesia. Generally, such diagnosis is made
by performing an endoscopy, colonscopy, sigmoidoscopy or
radiological technique which often must be done in a hospital
or clinic-like setting and sometimes requiring a biopsy of
apparently affected tissue. It is estimated that at least one
million Americans have Inflammatory Bowel Disease (IBD),
with about 50% having Crohn's disease and about 50% having ulcerative colitis. Because of health care costs and diagnostics, the actual estimated number of patients with IBD
may be significantly higher. Therefore it would be highly
desirable to have a diagnostic test that is less invasive, less
expensive and can accurately identify those patients with
MAP infection. Ultimately, treatment with appropriate antibiotics will go a long way toward relieving them from the
disease.
Based on the clinical similarities of animals infected with
paratuberculosis, early research suggested that the disease
which came to be known as Crohn's disease was caused by
mycobacteria Early studies on Crohn' s disease did not detect
MAP in tissues from patients with Crohn's disease by conventional staining and culture techniques because such
patients may have mycobacterium which are cell-wall deficient, and because of the difficulties in cultivating MAP, with
its slow growing characteristics. A research group at Baylor
College of Medicine patented the discovery of p36 (a protein
from MAP) for serologic detection of MAP antibodies from
Crohn's patients in U.S. Pat. No. 5,776,699. Researchers
have also recently utilized the insertion element IS 900 to
accurately identify MAP (Mishina, D Katsel, P Brown, S t
Gilberts, E C Greenstein R J "On the Etiology of Crohn
Disease" Proc Natl Acad Sci USA 1996, 93: 9816-20.) and
others have found MAP in tissue and breast milk samples
from lactating mothers with Crohn's disease (D. Schwartz et
al., "Use of short-term culture for identification of Myca bacterium avium subsp paratuberculosis in tissue from Crohn's
disease patients" Clin Microbial Infect 2000: 6, 303-307.
Naser, SA Schwartz, D. Shafran, I, "Isolation of Mycobacterium avium subsp paratuberculoisis from breast milk of
Crohn's disease patients" Am Jl Gastroenterol 2000,
95:1094-5.
At the present time, however, no one has provided a method
for diagnosing Crohn's disease that is caused by MAP (there
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A primary objective of the present invention is to provide
for using blood via PCR and culture to detect MAP.
A second objective of the invention is to provide a method
to diagnose those patients with Crohn' s disease or ulcerative
colitis caused by the bacterium.
A third objective of the invention is to ultimately select
those persons who would benefit by anti-MAP treatment.
A method is provided for monitoring and evaluating the
course of irritable bowel disease by determining the presence
or absence of irritable bowel disease caused by MAP after the
initial diagnosis, and through treatment.
A preferred method of diagnosing inflanimatory bowel
disease in those patients who have bowel disease caused by
Mycobacterium Avium Paratuberculosis (MAP) using a
sample of peripheral blood tissue includes selecting a blood
sample from at least a single patient of selected patients,
culturing that blood sample for a period of time sufficient to
obtain a sufficient growth of MAP to subject to PCR, and
detecting MAP therefrom.
The preferred method is used when the patient is a human
patient having inflammatory bowel disease which is known as
Crohn's disease, irritable bowel disease (IBD), or Ulcerative
colitis. A more preferred method further includes treating
MAP infected patients who have MAP detected in their blood
with an anti-MAP effective amount of an anti-MAP compound and a pharmaceutically acceptable excipient therefor.
A preferred method of treating MAP infected patients
includes using an anti-MAP compound that is an antibiotic in
an effective amount is an amount sufficient to eliminate MAP
from registering positive in a blood test.
The preferred method of treating MAP infected patients
includes a time required to culture the blood sample of from
approximately 8 weeks to approximately 12 weeks, preferably 12 weeks. The blood sample is cultured in media selective for MAP that includes Mycobacterial Growth Indicator
Tube (MGIT), BACTEC or BACTEC further supplemented
with 1% sucrose.
The preferred method of treating MAP infected patients
further includes the use of the PCR method to detect MAP
using one of more of the group consisting of Seq ID 1, Seq
ID2, Seq ID 3 and Seq ID 4 as primers for nested PCR or the
method can include the use of. primers that include one or
more of the group consisting of Seq ID 1, Seq ID 2, Seq ID 3
and Seq ID 4 and nucleotide polymorphisms thereof.
It is also within the present invention to use one or more of
Seq ID 1 or Seq ID 2 as primers in the first round of PCR and
one or more of Seq ID 3 or Seq ID 4 in the second round of
PCR.
The present invention also includes a preferred method for
monitoring and evaluating the course of inflanimatory bowel
disease caused by MAP that includes selecting a blood
sample from at least a single patient of selected patients,
culturing that blood sample for a period of time sufficient to
obtain a sufficient growth of MAP to subject to PCR, detect-
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ing MAP therefrom, obtaining a positive result for MAP, and
continuing to repeat said test at intervals throughout treatment.
The method for treatment of the inflammatory bowel disease known as Crohn's disease requires a volume of blood
extracted from the patient for use in the test in an amount of
approximately 4 mis or greater.
A preferred kit for use in diagnosing inflammatory bowel
disease caused by Mycobacterium Avium Paratuberculosis
(MAP) in blood includes primers, Seq ID 1, Seq ID2, Seq ID3
and SeqID4.
Further objects and advantages of this invention will be
apparent from the following detailed description of the presently preferred embodiments which are illustrated schematically in the accompanying drawings.

4 in FIG. 4) oligonucleotide primers in the second round to
re-amplify an 298 base pair internal nucleotide sequence for
the 398 base pair template as shown in FIG. 5. In FIG. 5,
positive results are indicated by a bright 298 bp band (arrow)
on 2% agarose gel electrophoresis. M=molecular weight
marker. Lane 1 represents DNA from MAP strain ATTC
43015 as a positive control (+); lanes A2 and B2 represent
negative controls for second round of nested PCR, lanes A3
and A4 represent negative controls for first round of nested
PCR and for DNA extraction steps, respectively. Positive and
negative controls were run along with each sample analysis.
For the composite image shown in FIG. 5, only representative
positive and negative controls are shown. FIG. 5 results are
shown for Crohn's Disease Patients, Ulcerative colitis (UC)
Patients and Patients with No Inflanimatory Bowel Disease
(Non-IBD).
The PCR conditions consisted of a reaction medium of
5-mM MgCl2, 0.2 mM dNTP, 6% DMSO or 0.5M Betaine, 2
micromolar primers and 2.5 units of Platinum Taq polymerase purchased from Invitrogen, Calsbad Calif. or 1 unit of
TFL DNA polymerase purchased from Promega, Madison,
Wi. and 10 microliters of DNA template. The PCR reaction
mixture in the second round of the nested PCR was the same,
except that 5 microliters of PCR product from the first round
was used as a template and the AV! andAV2 oligonucleotide
primers were substituted. The PCR cycling conditions were
95 degrees C. for 5 min, 34 cycles of95 degrees for 1 minute
and 58 degrees C. for 1.5 minutes, 72 degrees C. for 1.5
minutes and a final extension of 10 minutes at 72 degrees C.
The amplification product size was assessed on 2% agarose
gel, however one can also use real time PCR using the above
condition where agarose gel may not be needed for reading
the results. The same protocol may be applied using quantitative real time PCR.
Once positive tests are obtained using this method, patients
can be treated using anti-MAP compounds. Such compounds
may be antibiotics. Antibiotics with known specificities for
MAP are Clarithromycin, Rifabutin and Clofazimine.
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BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 is Seq ID l-P90 primer
FIG. 2 is Seq ID 2-P91 Primer
FIG. 3 is Seq ID 3-AVl Primer
FIG. 4 is Seq ID 4-AV2 Primer
FIG. 5 is an autoradiograph of Nested PCR detection of
MAP DNA from cultured peripheral blood samples
FIG. 6A is a drawing of microscopic MAP cultures isolated
from blood (5 week old MGIT culture from patient with
Crohn's disease)
FIG. 6B is a representative acid-fast positive MAP culture
from a patient with Crohn's disease after 12 weeks of incubation.
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DESCRIPTION OF THE PREFERRED
EMBODIMENTS
Before explaining the disclosed embodiments of the
present invention in detail it is to be understood that the
invention is not limited in its applications to the details of the
particular arrangements shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.
Blood samples were taken from patients, and drawn into
sterile K2-EDTA vacutainer tubes. A sample of each buffy
coat (the middle layer of blood products) were used to inoculate into media that is selective for Mycobacterium avian
subsp paratuberculosis (MAP). Such media may be Mycabacterial Growth Indicator Tubes (MGIT) or MGITpara (purchased from Becton Dickinson, Franklin Lake, N.J.) or
BACTEC (purchased from Beckton Dickinson, Franklin
Lake, N.J.) or other selective media and added to 4 ml of
modified Middlebrook 7H9 broth base. The media is optimally supplemented with 0.1 % sucrose, MycobactinJ (Allied
Monitor) and PANTA (Becton Dickinson, Franklin Lake,
N.J.) as described in Schwartz, D, Schafran, I, Romero, C, et
al. "Use of short-term culture for identification of Mycobacterium avium subsp paratuberculosis in tissue from Crohn's
disease patients." Clin Microbial Infect 2000, 6: 303-307.
MAP requires long term culturing, and the cultures were
incubated for 8-12 weeks.
Cultures were assessed for the presence of MAP by staining and then subjecting to nested PCR. Genomic DNA was
extracted and oligonucleotide primers were derived from the
DNA insertion sequence IS900, which is unique to MAP. The
primers P90 (Sequence ID 1 inFIG.1) andP91 (Sequence ID
2 in FIG. 2) were used for the first round to amplify a unique
398 bp fragment of the IS900 gene. The sensitivity and specificity forthe amplified MAP DNA fragment were achieved by
use of AV! (Sequence ID 3 in FIG. 3) andAV2 (Sequence ID
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Example 1
Patients and Samples: 52 participants were included in the
study: 28 with Crohn's disease, nine with ulcerative colitis
and 15 without inflanimatory bowel disease (two with colon
cancer, one with diverticulitis, one with gastrooesophageal
reflux and 11 healthy individuals). Informed consent was
obtained in accordance with institutional review board regulations at the University of Florida, Gainesville Veterans
Affairs Medical Center, and the University of Central Florida.
Of the patients with Crohn's disease, 22 of28 (78%) and all
the patients with ulcerative colitis were recruited from the
inflammatory bowel disease clinic at the University of
Florida, a tertiary referral centre. The diagnosis of Crohn's
disease or ulcerative colitis was established on standard clinical, endoscopic, histological, and radiographic criteria. Disease activity was assessed by use of the Harvey Bradshaw
index or the clinical findings of the treating physician. Only
one of the patients with Crohn's disease, and none of those
with ulcerative colitis, were newly diagnosed. Patients with
indeterminate colitis were excluded. Two 4-mL whole blood
samples drawn into sterile K2-EDTA Vacutainer tubes were
obtained from every participant. All samples were coded to
conceal the patient's identity and the diagnosis. The samples
were immediately processed in a class II biosafety cabinet.
The buffy coat layer from each tube was transferred into a
separate sterile tube that was used for either genomic DNA

US 7,488,580 Bl
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extraction or culture. A medication history was completed for
each participant as shown in Table 1. Use of prednisone,
budesonide, azathioprine, mercaptopurine, methotrexate, or
infliximab at any dose was judged to be immunosuppressive.
Products containing mesalamine were not considered to be
immunosuppressive. Procedures for culture, each buffy coat
sample was resuspended in 1 mL of sterile phosphate buffer
saline, pH 6.8. Samples (0.5 mL) of the suspension were used
to inoculate one MGIT and one 12B * BACTEC bottle (Beckton Dickinson, Franklin Lake, N.J., USA), each containing 4
mL of modified Middlebrook 7H9 broth base media (Becton
Dickinson) with supplements as previously described. All
inoculated culture media were incubated at 37° C. in a 5%
carbon dioxide incubator. The BACTEC bottles were
assessed every week with the BACTEC 460TB Analyzer
(Becton Dickinson) and the MGIT were checked every 2
weeks for visible turbidity and fluorescence-quenching activity with a 365 nm UV-illuminator. The BACTEC bottles with
a growth index reading of 50 or more, and all MGIT cultures
incubated for 8-12 weeks, were assessed for the presence of
MAP by staining and nested PCR. MAP cells were inactivated by heating the cell pellet from a 0-5 mL sample of the
culture in 500 µL TE buffer (10 mM Tris and 1 mM EDTA, pH
8.0 HCl) at 80° C. for 10 min. The sample was centrifuged at
10000 rpm (12800 g) for 5 min and the cell pellet was suspended in 150 µL of sterile water. 50 µL was used to prepare
smears for Ziehl-Neelsen staining, acridine orange staining,
or immunostaining with adsorbed rabbit-anti-MAP polyclonal IgG antibodies as described previously. The remaining
volume was used for extraction of genomic DNA for PCR
analysis.
Analysis of DNA: Genomic DNA was extracted from
uncultured buffy coat cells and cell culture pellets in a separate class II biosafety cabinet. The cells were re-suspended in
100 µL sterile TE buffer and incubated in a dry heat bath at
100° C. for 30 min, then placed on ice for 15 min. They were
then centrifuged at 12000 rpm (18500 g) and4° C. for 10 min.
The supernatant was transferred to 2.0 mL phase-lock gel
tubes (PLG, Eppendorf, Westbury, N.Y., USA). 200 µl of
phenol/chloroform/isoamyl alcohol (1: 1:24 v/v; Acros
Organics Morris Plains, N.J., USA) was added, mixed, and
centrifuged at 12000 rpm (18500 g) and 4 ° C. for 5 min. The
nucleic acid was precipitated, washed, dried, and dissolved in
50 µL of sterile water. Both primary and secondary rounds of
the nested PCR were done in a class II biosafety cabinet used
only for PCR. Oligonucleotide primers were derived from the
DNA insertion sequence IS900, which is unique to MAP. The
primers P90 and P91 (Sequence ID 1 in FIG. 1 and Sequence
ID 2 in FIG. 2, respectively) were used for the first round to
amplify a unique 398 bp fragment of the IS900 gene. The
sensitivity and specificity for the amplified MAP DNA fragment were achieved by use of AV! and AV2 oligonucleotide
primers (Sequence ID 3 in FIG. 3 and Sequence ID 4 in FIG.
4, respectively) in the second round to re-amplify an 298 bp
internal nucleotide sequence of the 398 bp template. The PCR
reaction mixture consisted of 40 µL PCR buffer: 5-mM
MgC12, 0.2 mM dNTP, 6% DMSO or 0.5 M Betaine, 2 µM
primers, and 2.5 U Platinum Taq polymerase (Invitrogen,
Carlsbad, Calif., USA) or 1 U TFL DNA polymerase
(Promega, Madison, Wis., USA) and 10 µl of DNA template.
The PCR reaction mixture in the second round of the nested
PCR was the same, except that 5 µL of PCR product from the
first round was used as a template and the AV! and AV2
oligonucleotide primers were substituted. The PCR cycling
conditions were: 95° C. for 5 min, 34 cycles of 95° C. for 1
min, 58° C. for 1.5 min, 72° C. for 15 min, and a final
extension of 10 min at 72° C. The amplification product size

was assessed on 2% agarose gel. Negative controls for PCR
consisted of sterile TE buffer or sterile water used in place of
the DNA template, and were used in parallel with every round
of PCR preparation. Positive MAP DNA from strain ATCC
43015 was prepared independently and added to PCR tubes at
a different facility using separate supplies. Nucleotide
sequencing verified the specificity of the amplified IS900
fragment. PCR products from the second round of the nested
PCR from positive samples were purified and sequenced at
the Biomolecular Science Center DNA Sequencing Core
facility at the University of Central Florida. BLAST and
alignment sequence analyses were also done.
Statistical Analysis: Groups were compared with 2x2 contingency tables and Fishers exact test. A positive (p) value of
less than 0.05 was judged to be significant. Results: The code
for concealment of participants' identities and diagnoses was
broken and data were tabulated after the conclusion of all
experiments (table 1). Participants were aged 18-77 years.
Overall, 50% were female; 17 (61 % ) of those with Crohn' s
disease, 2 (22%) of those with ulcerative colitis, and 7 (4 7%)
of those without inflammatory bowel disease. 16 ( 62%) of the
26 patients with Crohn's disease for whom data were available were known to be on immunosuppressive medications.
Four (44%) patients with ulcerative colitis and none of those
without inflammatory bowel disease were on such medications. Samples that were positive for the MAP-specific IS900
element clearly showed a single bright 298 bp band on 2%
agarose gel. MAP DNA was detectedin20 of52 (38%) of all
blood samples (table); 13 (46%) patients with Crohn's disease, four (44%) with ulcerative colitis, and three (20%)
without inflammatory bowel disease. None of the PCR internal controls, including one for genomic DNA extraction and
one in each round of the nested PCR, were positive for MAP
DNA, indicating no laboratory contamination. Nucleotide
sequencing of purified MAP DNA fragments from representative samples that were positive in the second round of the
nested PCR confirmed the amplification ofIS900 nucleotide
sequence. After 12 weeks of incubation, possible mycobacterial growth was detected in three of 52 BACTEC cultures.
Detection of possible mycobacterial growth in MGIT cultures inoculated with blood-derived buffy coat based on the
observation of visible turbidity and increase in fluorescence
intensity is unreliable. AB 52 MGIT cultures and the three
BACTEC cultures in which a possible mycobacterial growth
was detected were assessed for the presence of MAP. IS900nested PCR identified MAP in all three suspected BACTEC
cultures andin 14 of52 MGIT cultures. Only one patient was
positive for MAP by both culture methods. MAP was isolated
from culture in 14 (50%) patients with Crohn's disease, two
(22%) of those with ulcerative colitis, and none of those
without inflammatory bowel disease (p=0.0005 for group
with Crohn' s disease vs without inflanimatory bowel disease;
see FIG. 5). 11 of the 13 patients with Crohn's disease who
were positive for MAP DNA in blood by PCR were also
positive by culture, and ten of the 14 subsequently found to be
positive by culture had also tested positive by PCR. Of the
four PCR-positive patients with ulcerative colitis, one was
positive by culture; the other culture-positive ulcerative colitis patient was PCR negative. None of the three PCR-positive
individuals without inflammatory bowel disease was positive
by culture. Among the 26 Crohn' s disease patients for whom
data on the use of immunosuppressive medications were
available, current use of immunosuppressive medication did
not correlate with a positive culture result (p=0.23; table). The
sample size was too small to make any distinction about
specific immunosuppressive medications, age of onset, disease duration, or clinical phenotype. MAP-positive cultures
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ofbuffy coat were negative by acid-fast Ziehl-Neelsen staining during the early weeks of culture incubation, but were
positive by acridine orange or immunostaining with rabbit
anti-MAP IgG polyclonal antibodies as shown in FIG. 6A.
FIG. 6A is an illustration of a cell-wall-deficient MAP from
5-week-old MGIT culture from patient with Crohn's disease.
After 12 weeks of incubation, all 16 MAP-positive cultures
contained acid fast bacilli, with the occasional presence of
deformed cells containing renmant cell wall components,
also known as pre-spheroplasts as shown in FIG. 6B. FIG. 6B
is a representative acid-fast positive MAP culture from a
patient with Crohn's disease.

tutions (CG instead ofGC located at 114-115 of the 1451 bp
encoding sequence of the IS900 locus) in seven MAP clinical
isolates. Only one IS900 locus (accession number X16293)
showed no CG switching.
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope of
the invention is not intended to be, nor should it be deemed to
be, limited thereby and such other modifications or embodiments as may be suggested by the teachings herein are particularly reserved especially as they fall within the breadth
and scope of the claims here appended.

lO

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 4
<210>
<211>
<212>
<213>

SEQ ID NO 1
LENGTH, 20
TYPE, DNA
ORGANISM: mycobacterium Avium

<400> SEQUENCE, 1
gttcggggcc gtcgcttagg

<210>
<211>
<212>
<213>

20

SEQ ID NO 2
LENGTH, 20
TYPE, DNA
ORGANISM: mycobacterium Avium

<400> SEQUENCE, 2
gaggtcgatc gcccacgtga

<210>
<211>
<212>
<213>

20

SEQ ID NO 3
LENGTH, 22
TYPE, DNA
ORGANISM: mycobacterium Avium

<400> SEQUENCE, 3
atgtggttgc tgtgttggat gg

<210>
<211>
<212>
<213>

22

SEQ ID NO 4
LENGTH, 19
TYPE, DNA
ORGANISM: mycobacterium Avium

<400> SEQUENCE, 4
19

ccgccgcaat caactccag

To investigate the diversity of the MAP isolates, the 298 bp
was sequenced and amplifed IS900 fragment from 11 representative MAP-positive cultures. The nucleotidesequences
were assessed against each other, the sequence from the laboratory MAP strain (positive control), and several IS900 loci
available in the National Center for Biotechnology Information database (http://www.ncbi.nlm.nih.gov). All sequences
were confirmed as IS900. Nine of the 11 MAP isolates were
different from each other because of nucleotide polymorphisms including insertions, deletions, and substitutions. All
11 MAP isolates differed from the MAP-positive control used
in our laboratory. Of 11 IS900 loci published in the database,
ten (accession numbers AF416985, AJ250023, AJ250022,
AJ250015, AJ250016, AJ250017, AJ250018, AJ250019,
AJ250020, AJ250021) showed two consecutive base substi-

I claim:
55

60

65

1. A method of diagnosing inflammatory bowel disease in
those patients who have bowel disease caused by Mycobacterium avium subspecies paratuberculosis (MAP) using a
sample of peripheral blood tissue comprising the steps of:

selecting a blood sample from at least a single patient of
selected patients;
culturing the blood sample for a period of time sufficient to
obtain a sufficient growthofMAPto subject to PCR; and
detecting MAP therefrom, said PCR method used to detect
MAP comprising using one or more of the group consisting of SEQ ID NO: 1, SEQ ID N0:2, SEQ ID N0:3
and SEQ ID N0:4 as primers for nested PCR, said

US 7,488,580 Bl
9

10

patients being human patients, and said sample of blood
consisting of the buffy coat.
2. The method of claim 1, wherein the human patient has
inflammatory bowel disease selected from at least one of:
Crohn's disease, irritable bowel disease (IBD), and ulcerative
colitis.
3. The method of claim 1 wherein the inflammatory bowel
disease is Crohn's disease.
4. The method of claim 1, further comprising treating MAP
infected patients who have MAP detected in their blood with
an anti-MAP effective amount of an anti-MAP compound
and a pharmaceutically acceptable excipient therefor.
5. The method of claim 2, further comprising treating MAP
infected patients who have MAP detected in their blood with
an anti-MAP effective amount of an anti-MAP compound
and a pharmaceutically acceptable excipient therefor.
6. The method of claim 4 wherein said anti-MAP compound comprises an antibiotic.
7. The method of claim 6, wherein said effective amount is
an amount sufficient to eliminate MAP from registering positive in a blood test.
8. The method of claim 1 wherein the time required to
culture the blood sample is approximately 8 weeks to
approximately 12 weeks.
9. The method of claim 8, wherein the time required to
culture the blood sample is approximately 12 weeks.
10. The method of claim 1 where the blood sample is
cultured in media selective for MAP.
11. The method of claim 1 wherein the media selective for
MAP is selected from the group consisting ofMycobacterial
Growth Indicator Tube (MGIT) or BACTEC.
12. The method of claim 11, wherein the MGIT or
BACTEC is further supplemented with 1% sucrose.

13. The method of claim 1 wherein the primers comprise
one or more of the group consisting of Seq ID 1, Seq ID 2, Seq
ID 3 and Seq ID 4 and nucleotide polymorphisms thereof.
14. The method of claim 1 wherein one or more of Seq ID
1 or Seq ID 2 are used as primers in the first round of PCR and
one or more of Seq ID 3 or Seq ID 4 were used in the second
round of PCR.
15. The method, as in claim 13 wherein one or more of Seq
ID 1 or Seq ID 2 are used as primers in the first round of PCR
and one or more of Seq ID 3 or Seq ID 4 are used in the second
round of PCR.
16. A method for monitoring and evaluating the course of
inflammatory bowel disease caused by MAP comprising:
selecting a blood sample from at least a single patient of
selected patients;
culturing the blood sample for a period of time sufficient to
obtain a sufficient growth of MAP to subject to PCR;
detecting MAP therefrom;
obtaining a positive result from MAP; and
continuing to repeat said test at intervals throughout treatment wherein the method PCR method used to detect
MAP comprises using one of more of the group consisting of SEQ ID NO: 1, SEQ ID N0:2, SEQ ID N0:3 and
SEQ ID N0:4 as primers for nested PCR, said patients
being human patients, and said sample of blood consisting of the buffy coat.
17. The method, as in claim 16 wherein the inflammatory
bowel disease is Crohn's disease.
18. The method, as in claim 1 wherein the volume of blood
extracted from the patient for use in the test is 4 mis or greater.
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